156 related articles for article (PubMed ID: 33010623)
1. P2X7 receptor inhibition by 2-amino-3-aryl-1,4-naphthoquinones.
de Luna Martins D; Borges AA; E Silva NADA; Faria JV; Hoelz LVB; de Souza HVCM; Bello ML; Boechat N; Ferreira VF; Faria RX
Bioorg Chem; 2020 Nov; 104():104278. PubMed ID: 33010623
[TBL] [Abstract][Full Text] [Related]
2. Structure-based identification and characterisation of structurally novel human P2X7 receptor antagonists.
Caseley EA; Muench SP; Fishwick CW; Jiang LH
Biochem Pharmacol; 2016 Sep; 116():130-9. PubMed ID: 27481062
[TBL] [Abstract][Full Text] [Related]
3. Anti-Inflammatory Activity of 1,4-Naphthoquinones Blocking P2X7 Purinergic Receptors in RAW 264.7 Macrophage Cells.
Kozlovskiy SA; Pislyagin EA; Menchinskaya ES; Chingizova EA; Sabutski YE; Polonik SG; Likhatskaya GN; Aminin DL
Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668867
[TBL] [Abstract][Full Text] [Related]
4. Unique residues in the ATP gated human P2X7 receptor define a novel allosteric binding pocket for the selective antagonist AZ10606120.
Allsopp RC; Dayl S; Schmid R; Evans RJ
Sci Rep; 2017 Apr; 7(1):725. PubMed ID: 28389651
[TBL] [Abstract][Full Text] [Related]
5. The food dye FD&C Blue No. 1 is a selective inhibitor of the ATP release channel Panx1.
Wang J; Jackson DG; Dahl G
J Gen Physiol; 2013 May; 141(5):649-56. PubMed ID: 23589583
[TBL] [Abstract][Full Text] [Related]
6. Purinergic P2X7 receptor as a potential therapeutic target in depression.
Qi W; Jin X; Guan W
Biochem Pharmacol; 2024 Jan; 219():115959. PubMed ID: 38052270
[TBL] [Abstract][Full Text] [Related]
7. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.
Burnstock G; Knight GE
Purinergic Signal; 2018 Mar; 14(1):1-18. PubMed ID: 29164451
[TBL] [Abstract][Full Text] [Related]
8. P2X7R antagonism after subfailure overstretch injury of blood vessels reverses vasomotor dysfunction and prevents apoptosis.
Luo W; Feldman D; McCallister R; Brophy C; Cheung-Flynn J
Purinergic Signal; 2017 Dec; 13(4):579-590. PubMed ID: 28905300
[TBL] [Abstract][Full Text] [Related]
9. Natural compounds with P2X7 receptor-modulating properties.
Fischer W; Urban N; Immig K; Franke H; Schaefer M
Purinergic Signal; 2014; 10(2):313-26. PubMed ID: 24163006
[TBL] [Abstract][Full Text] [Related]
10. Purinergic P2X7 receptor antagonist ameliorates intestinal inflammation in postoperative ileus.
Kimura H; Yamazaki T; Mihara T; Kaji N; Kishi K; Hori M
J Vet Med Sci; 2022 Apr; 84(4):610-617. PubMed ID: 35249909
[TBL] [Abstract][Full Text] [Related]
11. P2X7 Receptor: an Emerging Target in Alzheimer's Disease.
Huang Q; Ying J; Yu W; Dong Y; Xiong H; Zhang Y; Liu J; Wang X; Hua F
Mol Neurobiol; 2024 May; 61(5):2866-2880. PubMed ID: 37940779
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer.
Drill M; Jones NC; Hunn M; O'Brien TJ; Monif M
Purinergic Signal; 2021 Jun; 17(2):215-227. PubMed ID: 33728582
[TBL] [Abstract][Full Text] [Related]
13. Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in response between rat and human.
Caseley EA; Muench SP; Baldwin SA; Simmons K; Fishwick CW; Jiang LH
Bioorg Med Chem Lett; 2015 Aug; 25(16):3164-7. PubMed ID: 26099538
[TBL] [Abstract][Full Text] [Related]
14. Curcumin amends Ca
Wang Z; Ren W; Zhao F; Han Y; Liu C; Jia K
Mol Cell Biochem; 2020 Feb; 465(1-2):65-73. PubMed ID: 31894530
[TBL] [Abstract][Full Text] [Related]
15. Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases.
Zheng H; Liu Q; Zhou S; Luo H; Zhang W
Front Immunol; 2024; 15():1345625. PubMed ID: 38370420
[TBL] [Abstract][Full Text] [Related]
16. ATP ion channel P2X7 receptor as a regulatory molecule in the progression of colorectal cancer.
Zuo C; Xu YS; He PF; Zhang WJ
Eur J Med Chem; 2023 Dec; 261():115877. PubMed ID: 37857146
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of natural product-derived compounds acting on P2X7R: The promising therapeutic drugs in disorders.
Liu Z; Liu W; Han M; Wang M; Li Y; Yao Y; Duan Y
Phytomedicine; 2024 Jun; 128():155334. PubMed ID: 38554573
[TBL] [Abstract][Full Text] [Related]
18. POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages.
Pimenta-Dos-Reis G; Torres EJL; Quintana PG; Vidal LO; Dos Santos BAF; Lin CS; Heise N; Persechini PM; Schachter J
Purinergic Signal; 2017 Dec; 13(4):611-627. PubMed ID: 29022161
[TBL] [Abstract][Full Text] [Related]
19. Involvement of microglial P2X7 receptor in pain modulation.
Zhang J; Gao L; Zhang Y; Wang H; Sun S; Wu LA
CNS Neurosci Ther; 2024 Jan; 30(1):e14496. PubMed ID: 37950524
[TBL] [Abstract][Full Text] [Related]
20. Mapping the Allosteric Action of Antagonists A740003 and A438079 Reveals a Role for the Left Flipper in Ligand Sensitivity at P2X7 Receptors.
Allsopp RC; Dayl S; Bin Dayel A; Schmid R; Evans RJ
Mol Pharmacol; 2018 May; 93(5):553-562. PubMed ID: 29535152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
